Bifidobacterium infantis and Enhanced Disease Resistance

• Genomic atlas of Bifidobacterium infantis and B. longum informs infant probiotic design.

  • 2026-03
  • Cell 189(6)
  • • Yan Shao
    • Shuyi Wang
    • Bonface M Gichuki
    • Mark D Stares
    • Timothy J Rozday
    • Nitin Kumar
    • Hilary P Browne
    • Nicholas J R Dawson
    • James M Njunge
    • Caroline Tigoi
    • Narshion Ngao
    • Mohammod Jobayer Chisti
    • Benson O Singa
    • Samuel Kariuki
    • Abdoulaye Hama Diallo
    • Ali Faisal Saleem
    • Syed Asad Ali
    • Ezekiel Mupere
    • Emmie Mbale
    • Kirkby D Tickell
    • Wieger P Voskuijl
    • Christina L Lancioni
    • Robert H J Bandsma
    • Tahmeed Ahmed
    • Judd L Walson
    • James A Berkley
    • Trevor D Lawley

  • PubMed: 41713418
  • DOI: 10.1016/j.cell.2026.01.007

  1 Insight on

  • Enhanced Disease Resistance

  • Moderate evidence
  • Rigorous Journal

  Bifidobacterium longum and B. infantis are pioneer colonizers of the neonatal gut and are widely used as probiotics to support infant growth, development, and disease resistance.

  Effect

  Beneficial

  Effect size

  Small